Phase 2 Endometrial Cancer Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have voluntarily agreed to participate and have signed a consent form.
• People who have been diagnosed with endometrial cancer (cancer of the lining of the uterus), confirmed through laboratory testing of tissue, where the cancer is advanced, has come back, or has spread, and surgery or radiation to cure it is not an option.
• People whose cancer did not respond to, or who could not tolerate, a standard first-line chemotherapy treatment containing platinum-based drugs.
• People who have at least one measurable area of cancer that can be tracked on scans, as confirmed by an independent medical review panel.
• People who are generally well enough to carry out light activity and care for themselves (a standard medical fitness score of 0 or 1).
• People with a life expectancy of at least 12 weeks.
• People whose blood counts and organ function (such as liver and kidneys) meet the required healthy levels, without having needed blood transfusions or certain growth-support treatments in the 14 days before starting the trial.
• People who can provide a stored or newly collected tumour tissue sample (from a spot that has not been treated with radiation) before starting the trial, for research testing.
• Women who could potentially become pregnant must have a negative blood pregnancy test within 7 days before starting the trial.

Who may not be able to join:

• People whose previous test results showed a specific genetic marker known as dMMR or MSI-H (confirm with trial site).
• People who have taken part in another experimental drug trial within the past 28 days, or who have received any anti-cancer treatment (such as chemotherapy, radiation, or targeted therapy) within the past 2 weeks.
• People who still have side effects from previous cancer treatments that have not improved to a mild or resolved level.
• People who have had major surgery within the past 28 days, or who have a wound, ulcer, or bone fracture that is not healing properly.
• People who have previously been treated with certain immunotherapy drugs that target specific immune system pathways (such as anti-PD-1, anti-PD-L1, anti-PD-L2, or anti-CTLA-4 treatments).
• People with high blood pressure that remains above 150/90 mmHg, even with blood pressure medication.
• People with serious or uncontrolled heart or brain blood vessel disease.
• People who have, or have had, an active autoimmune disease (where the immune system attacks the body), unless the condition only requires simple hormone replacement therapy or is a skin condition that does not need whole-body treatment.
• People who have needed regular steroid medications (above a low daily threshold) within the 14 days before starting the trial.
• People who have received a live-virus vaccine within 28 days before the planned trial start, or who plan to receive one during the trial.
• People who currently have, or are suspected to have, inflammation of the lungs not caused by infection.
• People with an active infection that requires medication to treat.
• People with active Hepatitis B or Hepatitis C.
• People who test positive for HIV.
• People with uncontrolled fluid build-up around the heart, lungs, or abdomen.
• People with active or symptomatic cancer that has spread to the brain or the lining around the brain, unless the brain metastases were previously treated, have been stable on scans for at least 4 weeks before the trial, and have not required steroid treatment for at least 2 weeks before starting.
• People who have had another cancer diagnosed within the past 5 years, except for certain treated skin cancers or cancers removed completely with surgery.
• People who have a known allergy or sensitivity to the study drugs or their ingredients.
• Women who are pregnant or breastfeeding, or who are unwilling to use a highly effective method of contraception throughout the study and for 6 months after the last dose.
• People who have previously received any treatment targeting a process called VEGF-directed angiogenesis (a way some cancers grow blood vessels) (confirm with trial site).
• People whose scans show cancer growing into or around major blood vessels.
• People with a history of a severe high blood pressure crisis or high-blood-pressure-related brain swelling.
• People with conditions that affect how the gut absorbs medicines, or who have had certain bowel surgeries, or any other condition that might affect how the study drug is absorbed.
• People who have had a serious bleeding episode within the 6 months before starting the trial.
• People whom the trial investigators judge to be unsuitable for the trial for other reasons.

Important: Always verify eligibility with the trial site directly before applying.